全文获取类型
收费全文 | 214477篇 |
免费 | 15520篇 |
国内免费 | 5045篇 |
专业分类
耳鼻咽喉 | 1556篇 |
儿科学 | 2789篇 |
妇产科学 | 3280篇 |
基础医学 | 24600篇 |
口腔科学 | 3700篇 |
临床医学 | 14912篇 |
内科学 | 25363篇 |
皮肤病学 | 2537篇 |
神经病学 | 12824篇 |
特种医学 | 7045篇 |
外国民族医学 | 2篇 |
外科学 | 16389篇 |
综合类 | 31220篇 |
现状与发展 | 22篇 |
一般理论 | 12篇 |
预防医学 | 19159篇 |
眼科学 | 2675篇 |
药学 | 28534篇 |
108篇 | |
中国医学 | 24246篇 |
肿瘤学 | 14069篇 |
出版年
2024年 | 525篇 |
2023年 | 2821篇 |
2022年 | 6397篇 |
2021年 | 8750篇 |
2020年 | 7511篇 |
2019年 | 6846篇 |
2018年 | 6786篇 |
2017年 | 7867篇 |
2016年 | 8045篇 |
2015年 | 7360篇 |
2014年 | 10052篇 |
2013年 | 13493篇 |
2012年 | 11590篇 |
2011年 | 13573篇 |
2010年 | 8976篇 |
2009年 | 8450篇 |
2008年 | 9977篇 |
2007年 | 10919篇 |
2006年 | 10242篇 |
2005年 | 9345篇 |
2004年 | 7983篇 |
2003年 | 7199篇 |
2002年 | 5726篇 |
2001年 | 5161篇 |
2000年 | 4322篇 |
1999年 | 3617篇 |
1998年 | 2864篇 |
1997年 | 2914篇 |
1996年 | 2621篇 |
1995年 | 2322篇 |
1994年 | 2265篇 |
1993年 | 1887篇 |
1992年 | 1750篇 |
1991年 | 1633篇 |
1990年 | 1392篇 |
1989年 | 1154篇 |
1988年 | 1095篇 |
1987年 | 997篇 |
1986年 | 947篇 |
1985年 | 1287篇 |
1984年 | 1047篇 |
1983年 | 802篇 |
1982年 | 838篇 |
1981年 | 682篇 |
1980年 | 658篇 |
1979年 | 536篇 |
1978年 | 324篇 |
1977年 | 274篇 |
1976年 | 263篇 |
1975年 | 201篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
82.
83.
目的探讨喉癌患者血小板表面血小板膜糖蛋白Ⅱb/Ⅲa纤维蛋白原受体(PAC-1)、血小板P-选择素(CD62P)阳性表达率以及与患者临床病理特征和复发的关系。方法选取2014年1月~2015年12月间在我院耳鼻喉科手术治疗的116例喉癌患者,随访≥2年,并选取同期在我院体检的健康人群60例为对照组,采用流式细胞仪检测法检测外周血PAC-1和CD62P阳性率,并分析与临床病理特征、复发的关系。结果喉癌患者PAC-1和CD62P阳性表达率分别为(17.82±1.76)%和(22.87±3.13)%,明显高于健康人群(P<0.05);而且在喉癌患者PAC-1表达和CD62P表达呈正相关性(r=0.238,P<0.05)。T3-T4分期或N2-N3分期患者PAC-1和CD62P阳性表达率高于T1-T2分期或N0-N1分期患者(P<0.05)。另外远处转移组PAC-1和CD62P阳性表达率高于未发生转移组(P<0.05);随访期间有24例患者复发,复发率为20.69%。复发喉癌患者PAC-1、CD62P阳性表达率分别为(17.02±0.85)%和(21.84±1.17)%,明显高于未复发的喉癌患者(P<0.05)。经Logistics回归分析,PAC-1和CD62P是喉癌患者复发的独立危险因素(P<0.05)。结论PAC-1和CD62P阳性表达率与喉癌患者T分期、淋巴结转移和远处转移密切相关,同时可作为喉癌局部复发、区域淋巴结转移、远处转移的预测指标。 相似文献
84.
85.
Micro‐evolution of the hepatitis B virus genome in hepatitis B e‐antigen‐positive carriers: Comparison of genotypes B and C at various immune stages
下载免费PDF全文
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
86.
Walid K. Abu Saleh Phillip Mason Odeaa Al Jabbari Hany Samir Brian A. Bruckner 《Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital》2015,42(6):569-571
The Impella 5.0, a percutaneously inserted left ventricular assist device, has been used to support patients who have severe heart failure or who are undergoing high-risk percutaneous coronary intervention. We report our surgical placement of the Impella 5.0, through a graft sewn to the aorta, to unload the left ventricle of a 59-year-old man who was undergoing venoarterial extracorporeal membrane oxygenation for postcardiotomy shock. The patient underwent successful placement of a long-term left ventricular assist device before his discharge from the hospital. The versatility of the Impella 5.0 is exemplified in this patient who was successfully bridged to long-term support. 相似文献
87.
88.
89.
Nirmanmoh Bhatia Buddhadeb Dawn Tariq S. Siddiqui Marcus F. Stoddard 《Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital》2015,42(1):16-24
Determining aortic stenosis (AS) severity is clinically important. Calculating aortic valve (AV) area by means of the continuity equation assumes a circular left ventricular outflow tract (LVOT). The full impact of this assumption in calculating AV area is unknown. Predictors of noncircular LVOT shape in patients with AS are undefined.In 109 adult patients with AS who underwent multiplanar transesophageal echocardiography, we calculated AV area by means of the standard continuity method and by a modified method involving planimetric LVOT area.We found 54 circular, 37 horizontal-oval, 8 vertical-oval, and 10 irregular LVOTs. Area derived by direct planimetry correlated better with the modified than the standard continuity method (r=0.89 vs r=0.85; both P=0.0001). Valve areas of patients with mild, moderate, or severe AS by planimetry were more often mischaracterized with use of the standard than modified method (29 vs 18; P <0.0001). Horizontal-oval AV area derived by planimetry (1.28 ± 0.55 cm2) was underestimated by the standard method (1.05 ± 0.47 cm2; P=0.001), but not by the modified method. Congenital AV morphology and low cardiac index were the only multivariate predictors of horizontal-oval shape. Low cardiac index was the only predictor of noncircular shape.More than half our patients with AS had noncircular LVOTs. Using the modified method reduces mischaracterizations of AS severity. Congenital AV morphology and low cardiac index predict horizontal-oval or noncircular shape. These data suggest the value of direct LVOT measurement to calculate AS severity in patients who have congenital AV or a low cardiac index. 相似文献
90.
Treatment of posterior eye diseases is more challenging than the anterior segment ailments due to a series of anatomical barriers and physiological constraints confronted by drug delivery to the back of the eye. In recent years, concerted efforts in drug delivery have been made to prolong the residence time of drugs injected in the vitreous humor of the eye. Our previous studies demonstrated that poly(ortho ester) (POE) nanoparticles were biodegradable/biocompatible and were capable of long-term sustained release. The objective of the present study was to investigate the safety and localization of POE nanoparticles in New Zealand white rabbits and C57BL/6 mice after intravitreal administration for the treatment of chronic posterior ocular diseases. Two concentration levels of POE nanoparticles solution were chosen for intravitreal injection: 1.5?mg/ml and 10?mg/ml. Our results demonstrate that POE nanoparticles were distributed throughout the vitreous cavity by optical coherence tomography (OCT) examination 14 days post-intravitreal injection. Intraocular pressure was not changed from baseline. Inflammatory or adverse effects were undetectable by slit lamp biomicroscopy. Furthermore, we demonstrate that POE nanoparticles have negligible toxicity assessed at the cellular level evidenced by a lack of glia activation or apoptosis estimation after intravitreal injection. Collectively, POE nanoparticles are a novel and nontoxic as an ocular drug delivery system for the treatment of posterior ocular diseases. 相似文献